What is claimed:

1. A method of reducing an HIV infected subject's HIV-1 viral load which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+ cell, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.

2. The method of claim 1, wherein the antibody is a monoclonal antibody.

3. The method of claim 1, wherein the antibody is selected from the group consisting of PA8 (ATCC Accession No. HB-12605), PA9 (ATCC Accession No. HB-12606), PA10 (ATCC Accession No.HB-12607), PA11 (ATCC Accession No. HB-12608), PA12 (ATCC Accession No. HB-12609), and PA14 (ATCC Accession No. HB-12610).

4. The method of claim 1, wherein the antibody is PA14 (ATCC Accession No. HB-12610).

5. The method of claim 1, wherein the subject's HIV-1 viral load is reduced to 33% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.

6. The method of claim 1, wherein the subject's HIV-1 viral load is reduced to 10% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.

7. The method of claim 1, wherein the reduction of the subject's HIV-1 viral load is sustained for a period of time.

Sub B2

8. The method of claim 7, wherein the period of time is at least one day.

9. The method of claim 7, wherein the period of time is at least three days.

10. The method of claim 7, wherein the period of time is at least seven days.

11. The method of claim 1, wherein the effective amount of the antibody is between about 1mg and about 50mg per kg body weight of the subject.

12. The method of claim 11, wherein the effective amount of the antibody is between about 2mg and about 40mg per kg body weight of the subject.

13. The method of claim 12, wherein the effective amount of the antibody is between about 3mg and about 30mg per kg body weight of the subject.

14. The method of claim 13, wherein the effective amount of the antibody is between about 4mg and about 20mg per kg body weight of the subject.

15. The method of claim 14, wherein the effective amount of the antibody is between about 5mg and about 10mg per kg body weight of the subject.

16. The method of claim 1, wherein the antibody is

administered at least once per day.

17. The method of claim 1, wherein the antibody is administered daily.

18. The method of claim 1, wherein the antibody is administered every other day.

19. The method of claim 1, wherein the antibody is administered every 6 to 8 days.

20. The method of claim 1, wherein the antibody is administered weekly.

21. The method of claim 1, wherein the antibody is administered intravenously, subcutaneously, intramuscularly, intraperitoneally, orally or topically.

22. The method of claim 1, wherein the subject is a human being and the antibody is a humanized antibody.